UPDATE: Bloom Burton Cuts PT to $24 on OncoGenex Pharmaceuticals

Bloom Burton lowers its price target on BUy-rated OncoGenex Pharmaceuticals (NASDAQ: OGXI to $24 as the timing of Custirsen approval is pushed back Bloom Burton notes, "Price target decreased to $24.00 from $28.00. This is mainly due to pushing back our timing of custirsen approval for second-line chemotherapy use from 2016 to 2018. We have also rolled forward our valuation by one year." OGXI closed at $15.70 a share on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetReiterationIntraday UpdateAnalyst RatingsBloom Burton
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!